Project Grant R01CA292236
Award Date
9/5/24
Completion Date
8/30/29
Dollars Obligated
$623K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This $753,446 Project Grant award from the National Cancer Institute's Cancer Cause and Prevention Research program (CFDA 93.393) aims to adapt and test an intervention to improve cervical cancer screening and follow-up in three diverse, underserved populations: urban inner city Blacks/Haitians in Boston, Hispanic immigrants in Florida, and Hawaiian Natives/Pacific Islanders in Hawaii. The intervention combines education and quality improvement methods using a mechanism called Performance...
The University of California, San Diego (UCSD) received a $697,198 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to develop a targeted colorectal cancer (CRC) screening strategy for adults aged 45-49. The study aims to characterize the acceptability of CRC screening in this population, identify factors influencing screening uptake, and evaluate the comparative effectiveness of an active outreach strategy including mailed fecal...
This Project Grant award of $637,596 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research to develop and test an intervention to reduce cancer information avoidance and increase colorectal cancer screening. The key products and services being delivered under this 5-year grant, which began on April 4, 2025, include: Conducting a randomized controlled trial to evaluate the effects of a video-based intervention on screening intentions and...
This Project Grant award of $1,400,269.00 from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research (CFDA 93.393) program, supports research to optimize a mobile messaging intervention to increase colorectal cancer (CRC) screening completion among patients at community health centers (CHCs). The project, which runs from May 1, 2025 to Apr 30, 2030, will use a two-phase process to first determine optimal messaging strategies for maximizing patient engagement, and...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) provides $197,640 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop implementation strategies to initiate colorectal cancer (CRC) screening in previously unscreened individuals aged 45 to 54 at a predominantly Black community health center in Boston, Massachusetts. The key objectives are to: (1) identify system-level determinants of...
This National Cancer Institute (NCI) Project Grant award under CFDA 93.395 "Cancer Treatment Research" provides $196,267 in funding to the University of California, Irvine (UCI) to advance novel cancer prevention and therapeutic strategies across NCI's clinical trial networks. The award will support the Principal Investigator's leadership roles on key NCI committees, completion of an ongoing Phase III clinical trial focused on preventing colorectal adenomas in a racially/ethnically...
This $456,764 Project Grant awarded by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will support research by the University of Chicago to study differences in bile acid metabolism and colonic responses between African Americans and non-Hispanic whites. The research aims to elucidate how environmental factors influenced by social determinants of health, particularly diet, may contribute to disparities in colorectal cancer incidence and mortality between these...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $1,403,822.00 to the University of Chicago to conduct a multi-center, prospective trial examining the performance of the fecal immunochemical test (FIT) for colorectal cancer surveillance in patients with Lynch syndrome. The key objectives are to measure FIT test characteristics, evaluate patient attitudes and acceptability of non-invasive tests, and develop a...
The Project Grant award of $300,000.00 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) will support a study on the epidemiology of the gut-liver axis and its relationship to hepatocellular carcinoma (HCC) risk in a multiethnic liver cirrhosis cohort. The study aims to expand the existing Microbiome, Microbial Markers, and Liver Disease (M3LD) cohort by enrolling approximately 1,000 participants with liver cirrhosis, with a focus on...
This $2,136,715 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) is focused on harnessing DNA methylation in peripheral blood to improve colorectal cancer prevention. The primary awardee, President and Fellows of Harvard College through its Harvard T.H. Chan School of Public Health, will lead the research effort. Key sub-awards have been made to Dana-Farber Cancer Institute and Boston University to contribute...